West Pharmaceutical Services (WST) Capital Expenditures (2009 - 2026)

West Pharmaceutical Services' Capital Expenditures history runs 18 years deep, the most recent figure standing at $26.1 million for Q1 2026.

• In Q1 2026, Capital Expenditures fell 63.39% year-over-year to $26.1 million; the TTM figure through Mar 2026 stood at $240.7 million (up 206.23% YoY), while the FY2025 annual figure was $285.9 million, up 439.43% from the prior year.
• Capital Expenditures came in at $26.1 million for Q1 2026 at West Pharmaceutical Services, down from $76.1 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $230.5 million in Q3 2024 to a low of -$219.1 million in Q4 2024.
• A 5-year average of $44.7 million and a median of $66.1 million in 2022 frame the typical range for Capital Expenditures.
• Across the five-year window, Capital Expenditures tumbled 301.56% in 2024 and surged 1934.15% in 2025, its largest moves.
• West Pharmaceutical Services' Capital Expenditures stood at -$156.5 million in 2022, then soared by 169.46% to $108.7 million in 2023, then plunged by 301.56% to -$219.1 million in 2024, then jumped by 134.73% to $76.1 million in 2025, then plunged by 65.7% to $26.1 million in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $26.1 million, $76.1 million, and $63.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison